Advertisement

Topics

LIP-01 in Hypercholesterolemia

2014-07-23 21:13:32 | BioPortfolio

Summary

The purpose of this study is to determine a safe and tolerable dose of LIP-01

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Hypercholesterolemia

Intervention

LIP-01

Location

The Northern Alberta Clinical Trials and Research Centre
Edmonton
Alberta
Canada
T6G 2C8

Status

Recruiting

Source

Afexa Life Sciences Inc

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:13:32-0400

Clinical Trials [226 Associated Clinical Trials listed on BioPortfolio]

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lo...

An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia

The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).

Evaluation of the Effects of Simvastatin 40mg on Lipid Profiles and Cardiac Function and Structures in Hypercholesterolemia Patients

To collect lipid-lowering response data with the use of simvastatin 40 mg tablet in patients with hypercholesterolemia.

Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia

The purpose of the study is to determine whether an Internet based compliance tool is superior to common diet counselling in patients with hypercholesterolemia.

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

The purpose of the first part of this study is to determine the safety and tolerability of a single dose of AEM-28, an apolipoprotein E mimetic, in subjects with high total cholesterol who...

PubMed Articles [92 Associated PubMed Articles listed on BioPortfolio]

Retinal microvascular dysfunction in hypercholesterolemia.

Hypercholesterolemia is one of the most important contributors to atherosclerosis. Whether hypercholesterolemia also affects the retinal microcirculation is unclear.

Predicting cardiovascular disease in familial hypercholesterolemia.

Familial hypercholesterolemia is a frequent genetic disease associated with a high lifetime risk of cardiovascular disease (CVD). Statins are the cornerstone of treatment of familial hypercholesterole...

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.

Lipoprotein-associated phospholipase A(Lp-PLA) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Fa...

Clinical, Anthropometric and Biochemical Characteristics of Patients with or without Genetically Confirmed Familial Hypercholesterolemia.

Familial hypercholesterolemia (FH) is a common autosomal dominant disorder, characterized by a high level of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular dis...

Association of recipient and donor hypercholesterolemia prior allogeneic stem cell transplantation and graft-versus-host disease.

Few authors have reported a decreased frequency of acute graft-versus-host disease (aGVHD) using statins, as these medications have anti-inflammatory effects, however, to date, the direct association ...

Medical and Biotech [MESH] Definitions

An allylamine derivative that binds BILE ACIDS in the intestine and is used as an ANTICHOLESTEREMIC AGENT in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.

A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES.

An oily liquid extracted from the seeds of the safflower, Carthamus tinctorius. It is used as a dietary supplement in the management of HYPERCHOLESTEROLEMIA. It is used also in cooking, as a salad oil, and as a vehicle for medicines, paints, varnishes, etc. (Dorland, 28th ed & Random House Unabridged Dictionary, 2d ed)

More From BioPortfolio on "LIP-01 in Hypercholesterolemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial